|
Figure
1
schematically illustrates the effects of this invention.
The therapeutic effects T are illustrated above the
horizontal line and the adverse effects A below the
horizontal line. Zones
1 and 2 concern a known medicament used alone. It has
an amount of therapeutic effect 1 over a given disease
and an amount of adverse effects 2.
The
right part of figure 1 concerns
the complex according to the invention, of an OGC with
the same medicament. Over said given disease the considerably
increased therapeutic efficiency is illustrated by zones
3, and the adverse effects 4 are reduced.
Moreover
other therapeutic effects
6a
(antihypoxiceffect),
[definition: against hypoxia;
or against the reduction of oxygen supply to tissue
below physiological levels despite adequate perfusion
of the tissue by blood; or against anemic hypoxia for
instance.]
6b
(Immuno potentiating effect), [definition:
potentiating: potentiation: the synergistic action
of two drugs, being greater than the sum of the effects
of each used alone.]
6c (anti inflammatory effect),
6d (Reparative effect) and
6e (Nootropic effect)
[definition: Nootropic:
a synonym for psychotropic and was first proposed (1972)
by Mr. K. Jourges, the author of a medicine called "Pyracetam"
which activates the integral functions of the brain,
stimulates learning mechanisms and improves memory and
intellectual capacities. The term is very common
in the countries of Eastern and Central Europe
appear. (five new items appear)
All the zones marked with a cross correspond to therapeutic
improvement due to the invention.
This
Figure is taken from the Patent Pending Claims.
|
